Adefovir (Synonyms: 阿德福韋; GS-0393; PMEA)

目錄號(hào): HY-B1826 純度: 99.55%: Data Sheet SDS COA 產(chǎn)品使用指南技術(shù)支持

溶解度

動(dòng)物溶解方案

Adefovir (GS-0393) 是一種單磷酸腺苷類(lèi)似物抗病毒劑，在細(xì)胞內(nèi)轉(zhuǎn)化為 Adefovir diphosphate 后可抑制 HBV DNA 聚合酶。Adefovir 在 HepG2.2.15 細(xì)胞系中對(duì) HBV 的 IC₅₀ 為 0.7 μM。Adefovir 對(duì)多種病毒(包括 HBV 和皰疹病毒)具有良好的抗病毒活性。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Adefovir Chemical Structure

CAS No. : 106941-25-7

1. 客戶無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2. 同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價(jià)格	是否有貨
10 mg	￥340	In-stock
25 mg	￥500	In-stock
50 mg	￥800	In-stock
100 mg	￥1200	In-stock
200 mg		詢價(jià)
500 mg		詢價(jià)

or 大包裝詢價(jià)

* Please select Quantity before adding items.

Customer Review

Other Forms of Adefovir:

Adefovir-d₄ In-stock
Adefovir-d4 diphosphate triethylamine 詢價(jià)

MCE 顧客使用本產(chǎn)品發(fā)表的 1 篇科研文獻(xiàn)

•Molecules. 2022 May 18;27(10):3223. [Abstract]

Adefovir 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

生物活性
純度 & 產(chǎn)品資料
參考文獻(xiàn)

生物活性

Adefovir (GS-0393) is an adenosine monophosphate analog antiviral agent that after intracellular conversion to Adefovir diphosphate inhibits HBV DNA polymerase. Adefovir has an IC₅₀ of 0.7 μM against HBV in the HepG2.2.15 cell line. Adefovir has good antiviral activity against several viruses, including HBV and herpesviruses^[1]^[2]^[3].

IC₅₀ & Target

HBV^[1]^[2]^[3];
DNA polymerase^[1]^[2]

細(xì)胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
C-33-A	IC₅₀	7.8 μM Compound: 1, PMEA	Antiproliferative activity against human C33A cells after 72 hrs by flow cytometric analysis Antiproliferative activity against human C33A cells after 72 hrs by flow cytometric analysis	[PMID: 24686012]
C3H/3T3	EC₅₀	0.53 μM Compound: PMEA, Adefovir	Inhibition of murine sarcoma virus-induced transformation of mouse embryo fibroblast C3H/3T3 cells after 6 days Inhibition of murine sarcoma virus-induced transformation of mouse embryo fibroblast C3H/3T3 cells after 6 days	[PMID: 18556209]
C3H/3T3	EC₅₀	2.1 μM Compound: PMEA	Antiviral against Moloney murine sarcoma virus infected in mouse C3H/3T3 cells assessed as inhibition of virus-induced cell transformation after 6 days post infection by microscopic analysis Antiviral against Moloney murine sarcoma virus infected in mouse C3H/3T3 cells assessed as inhibition of virus-induced cell transformation after 6 days post infection by microscopic analysis	[PMID: 21429755]
C8166	EC₅₀	1.7 μM Compound: PMEA	Concentration required to inhibit p24 viral antigen production by 50% in C-8166 cells Concentration required to inhibit p24 viral antigen production by 50% in C-8166 cells	10.1016/0960-894X(95)00208-B
C8166	EC₅₀	7 μM Compound: PMEA, Adefovir	Antiviral activity against 100 TCID50 wild-type Human immunodeficiency virus type 2 ROD infected in C8166 cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis Antiviral activity against 100 TCID50 wild-type Human immunodeficiency virus type 2 ROD infected in C8166 cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis	[PMID: 21803462]
CCRF-CEM	CC₅₀	≥ 250 μM Compound: PMEA	Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 72 hrs by coulter counter analysis Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 72 hrs by coulter counter analysis	[PMID: 21429755]
CCRF-CEM	EC₅₀	10.4 μM Compound: 1, PMEA, Adefovir	Antiviral activity against HIV 1 3B infected in CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopy Antiviral activity against HIV 1 3B infected in CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopy	[PMID: 21565516]
CCRF-CEM	CC₅₀	164 μM Compound: 1, PMEA, Adefovir	Cytotoxicity against human CEM cells assessed as growth inhibition after 3 days by coulter counting analysis Cytotoxicity against human CEM cells assessed as growth inhibition after 3 days by coulter counting analysis	[PMID: 21565516]
CCRF-CEM	EC₅₀	18 μM Compound: PMEA	In vitro anti -HIV activity tested against CEM cells infected with HIV by XTT assay In vitro anti -HIV activity tested against CEM cells infected with HIV by XTT assay	[PMID: 1323678]
CCRF-CEM	IC₅₀	24 μM Compound: 1, PMEA	Cytostatic activity against human CEM cells after 72 hrs by coulter counting analysis Cytostatic activity against human CEM cells after 72 hrs by coulter counting analysis	[PMID: 24686012]
CCRF-CEM	EC₅₀	5.5 μM Compound: PMEA, Adefovir	Antiviral activity against 100 TCID50 wild-type Human immunodeficiency virus 1 3B infected in CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis Antiviral activity against 100 TCID50 wild-type Human immunodeficiency virus 1 3B infected in CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis	[PMID: 21803462]
CCRF-CEM	EC₅₀	7 μM Compound: PMEA, adefovir	Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human CEM cells assessed as HIV-induced CEM giant cell formation after 4 days by microscopy Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human CEM cells assessed as HIV-induced CEM giant cell formation after 4 days by microscopy	[PMID: 21745746]
CCRF-CEM	EC₅₀	7 μM Compound: PMEA	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced syncytium formation after 4 to 5 days by microscopic analysis Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced syncytium formation after 4 to 5 days by microscopic analysis	[PMID: 21429755]
CCRF-CEM	EC₅₀	7.4 μM Compound: PMEA, adefovir	Antiviral activity against Human immunodeficiency virus type1 3B infected in human CEM cells assessed as HIV-induced CEM giant cell formation after 4 days by microscopic analysis Antiviral activity against Human immunodeficiency virus type1 3B infected in human CEM cells assessed as HIV-induced CEM giant cell formation after 4 days by microscopic analysis	[PMID: 21745746]
CCRF-CEM	EC₅₀	7.4 μM Compound: PMEA	Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced syncytium formation after 4 to 5 days by microscopic analysis Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced syncytium formation after 4 to 5 days by microscopic analysis	[PMID: 21429755]
CCRF-CEM	EC₅₀	8.2 μM Compound: 1, PMEA	Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis	[PMID: 24686012]
CCRF-CEM	EC₅₀	8.4 μM Compound: 1, PMEA	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis	[PMID: 24686012]
CCRF-CEM	EC₅₀	8.6 μM Compound: 1, PMEA, Adefovir	Antiviral activity against HIV 2 ROD infected in CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopy Antiviral activity against HIV 2 ROD infected in CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopy	[PMID: 21565516]
CHO	CC₅₀	≥ 2000 μM Compound: Adefovir	Cytotoxicity against CHO cells after 120 hrs by Cell-Titer Glo assay Cytotoxicity against CHO cells after 120 hrs by Cell-Titer Glo assay	[PMID: 19001108]
CHO	CC₅₀	1.4 μM Compound: Adefovir	Ratio of CC50 for CHO cells to CC50 for CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay Ratio of CC50 for CHO cells to CC50 for CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay	[PMID: 19001108]
CHO	CC₅₀	3 μM Compound: Adefovir	Cytotoxicity against CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay Cytotoxicity against CHO cells expressing hOAT1 after 120 hrs by Cell-Titer Glo assay	[PMID: 19001108]
H9	CC₅₀	> 30 μM Compound: PMEA, Adefovir	Cytotoxicity against PAP-activated human H9 cells on day 7 by MTT assay Cytotoxicity against PAP-activated human H9 cells on day 7 by MTT assay	[PMID: 21803462]
H9	EC₅₀	1.1 μM Compound: PMEA, Adefovir	Antiviral activity against 125 TCID50 wild type HIV1 LAI infected in human H9 cells assessed as reduction in viral replication measured on day 7 post infection by reverse transcriptase activity Antiviral activity against 125 TCID50 wild type HIV1 LAI infected in human H9 cells assessed as reduction in viral replication measured on day 7 post infection by reverse transcriptase activity	[PMID: 21803462]
H9	EC₅₀	7.9 μM Compound: PMEA, Adefovir	Antiviral activity against 6250 TCID50 wild type HIV1 LAI infected in human H9 cells assessed as reduction in viral replication measured on day 7 post infection by reverse transcriptase activity Antiviral activity against 6250 TCID50 wild type HIV1 LAI infected in human H9 cells assessed as reduction in viral replication measured on day 7 post infection by reverse transcriptase activity	[PMID: 21803462]
HEK-293T	CC₅₀	> 100 μM Compound: PMEA	Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method	[PMID: 17470654]
HEL 299	EC₅₀	> 183 μM Compound: 3a, PMEA	Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining	[PMID: 17893157]
HEL 299	EC₅₀	> 183 μM Compound: 3a, PMEA	Antiviral activity against Camelpox virus CML14 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining Antiviral activity against Camelpox virus CML14 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining	[PMID: 17893157]
HEL 299	CC₅₀	211 μM Compound: 3a, PMEA	Cytotoxicity against HEL299 cells after 4 days by Z1 Coulter counting analysis Cytotoxicity against HEL299 cells after 4 days by Z1 Coulter counting analysis	[PMID: 17893157]
HeLa	CC₅₀	> 250 μM Compound: 1, PMEA, Adefovir	Cytotoxicity against human HeLa cells assessed as growth inhibition after 3 days by coulter counting analysis Cytotoxicity against human HeLa cells assessed as growth inhibition after 3 days by coulter counting analysis	[PMID: 21565516]
HeLa	IC₅₀	181 μM Compound: 1, PMEA	Cytostatic activity against human HeLa cells after 72 hrs by coulter counting analysis Cytostatic activity against human HeLa cells after 72 hrs by coulter counting analysis	[PMID: 24686012]
HepG2	IC₅₀	42.1 μM Compound: PMEA, 1	Antiviral activity against Hepatitis B virus infected human HepG2 cells after 9 days by MTT assay Antiviral activity against Hepatitis B virus infected human HepG2 cells after 9 days by MTT assay	[PMID: 17888662]
HepG2 2.2.15	IC₅₀	0.517 μM Compound: adefovir	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBV DNA replication after 9 days by PCR Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBV DNA replication after 9 days by PCR	[PMID: 20000776]
HepG2 2.2.15	IC₅₀	0.517 μM Compound: Adefovir	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication after 9 days by fluorescence PCR method Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication after 9 days by fluorescence PCR method	[PMID: 23353737]
HepG2 2.2.15	EC₅₀	1.3 μM Compound: Adefovir	Antiviral activity against wild type Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization method Antiviral activity against wild type Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization method	[PMID: 21930377]
HepG2 2.2.15	EC₅₀	1.6 μM Compound: Adefovir	Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204V mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204V mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me	[PMID: 21930377]
HepG2 2.2.15	EC₅₀	1.9 μM Compound: Adefovir	Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204I mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204I mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me	[PMID: 21930377]
HepG2 2.2.15	EC₅₀	2.1 μM Compound: Adefovir	Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V double mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hyb Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V double mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hyb	[PMID: 21930377]
HepG2 2.2.15	CC₅₀	200 μM Compound: Adefovir	Cytotoxicity in human HepG2.215 cells assessed as reduction in cell viability after 5 days by CCK8 assay Cytotoxicity in human HepG2.215 cells assessed as reduction in cell viability after 5 days by CCK8 assay	[PMID: 28082068]
HepG2 2.2.15	IC₅₀	215 μM Compound: Adefovir	Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as HBeAg secretion after 9 days by ELISA Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as HBeAg secretion after 9 days by ELISA	[PMID: 25650312]
HepG2 2.2.15	IC₅₀	257 μM Compound: Adefovir	Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as surface antigen HBsAg secretion after 9 days by ELISA Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as surface antigen HBsAg secretion after 9 days by ELISA	[PMID: 25650312]
HepG2 2.2.15	IC₅₀	286 μM Compound: Adefovir	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBeAg production after 9 days by ELISA Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBeAg production after 9 days by ELISA	[PMID: 23353737]
HepG2 2.2.15	IC₅₀	286 μM Compound: adefovir	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBeAg level after 9 days by ELISA Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBeAg level after 9 days by ELISA	[PMID: 20000776]
HepG2 2.2.15	IC₅₀	305 μM Compound: Adefovir	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBsAg production after 9 days by ELISA Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBsAg production after 9 days by ELISA	[PMID: 23353737]
HepG2 2.2.15	IC₅₀	305 μM Compound: adefovir	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBsAg level after 9 days by ELISA Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBsAg level after 9 days by ELISA	[PMID: 20000776]
HepG2 2.2.15	CC₅₀	490 μM Compound: Adefovir	Cytotoxicity against human HepG2.2.15 cells assessed as cell death after 9 days by MTS assay Cytotoxicity against human HepG2.2.15 cells assessed as cell death after 9 days by MTS assay	[PMID: 25650312]
HepG2 2.2.15	EC₅₀	5.5 μM Compound: Adefovir	Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me	[PMID: 21930377]
HepG2 2.2.15	CC₅₀	540 μM Compound: Adefovir	Cytotoxicity against human HepG2(2.2.15) cells compound treated for 48 hrs followed by incubation for 9 days by MTT assay Cytotoxicity against human HepG2(2.2.15) cells compound treated for 48 hrs followed by incubation for 9 days by MTT assay	[PMID: 23353737]
HepG2 2.2.15	CC₅₀	57 μM Compound: adefovir	Cytotoxicity against HepG2.2.15 cells after 6 hrs by MTT assay Cytotoxicity against HepG2.2.15 cells after 6 hrs by MTT assay	[PMID: 17499889]
HepG2 2.2.15	EC₅₀	7.8 μM Compound: Adefovir	Antiviral activity against adefovir-resistant Hepatitis B virus harboring reverse transcriptase N236T mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization meth Antiviral activity against adefovir-resistant Hepatitis B virus harboring reverse transcriptase N236T mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization meth	[PMID: 21930377]
Huh-7	EC₅₀	1.3 μM Compound: adefovir	Antiviral activity against adefovir-resistant wild type HBV in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against adefovir-resistant wild type HBV in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	1.5 μM Compound: adefovir	Antiviral activity against adefovir-resistant HBV reverse transcriptase M204V mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against adefovir-resistant HBV reverse transcriptase M204V mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	1.6 μM Compound: adefovir	Antiviral activity against adefovir-resistant HBV reverse transcriptase L180M mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against adefovir-resistant HBV reverse transcriptase L180M mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	1.6 μM Compound: adefovir	Antiviral activity against adefovir-resistant HBV reverse transcriptase LM/reverse transcriptase MV double mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against adefovir-resistant HBV reverse transcriptase LM/reverse transcriptase MV double mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	1.8 μM Compound: adefovir	Antiviral activity against adefovir-resistant HBV reverse transcriptase M204I mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against adefovir-resistant HBV reverse transcriptase M204I mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	6 μM Compound: PMEA, Adefovir	Antiviral activity against Hepatitis B virus infected in human HuH7 cells assessed as reduction in viral DNA level treated day 3 to day 8 post transfection by real time quantitative PCR analysis Antiviral activity against Hepatitis B virus infected in human HuH7 cells assessed as reduction in viral DNA level treated day 3 to day 8 post transfection by real time quantitative PCR analysis	[PMID: 21803462]
Huh-7	EC₅₀	7.7 μM Compound: adefovir	Antiviral activity against adefovir-resistant HBV reverse transcriptase 236T mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against adefovir-resistant HBV reverse transcriptase 236T mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
L1210	IC₅₀	3 μM Compound: 1, PMEA	Cytostatic activity against mouse L1210 cells after 48 hrs by coulter counting analysis Cytostatic activity against mouse L1210 cells after 48 hrs by coulter counting analysis	[PMID: 24686012]
MT4	EC₅₀	22 μM Compound: PMEA	Concentration required to inhibit HIV-1-induced cytopathic effect by 50% in MT-4 cells Concentration required to inhibit HIV-1-induced cytopathic effect by 50% in MT-4 cells	10.1016/0960-894X(95)00208-B
PBMC	CC₅₀	> 30 μM Compound: PMEA, Adefovir	Cytotoxicity against PAP-activated human PBMC on day 7 by MTT assay Cytotoxicity against PAP-activated human PBMC on day 7 by MTT assay	[PMID: 21803462]
Vero	IC₅₀	119 μM Compound: 1	Concentration that reduced plaque formation by 50% was measured in HSV-2 infected vero cells in vitro Concentration that reduced plaque formation by 50% was measured in HSV-2 infected vero cells in vitro	[PMID: 8021925]
WI-38	CC₅₀	124.7 μM Compound: PMEA	Cytotoxicity against human WI38 cells by neutral red assay Cytotoxicity against human WI38 cells by neutral red assay	[PMID: 18285481]
WI-38	EC₅₀	95.8 μM Compound: PMEA	Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis	[PMID: 18285481]

體外研究
(In Vitro)

Adefovir 對(duì)皰疹病毒復(fù)制的作用機(jī)制的研究表明，Adefovir 的磷酸化發(fā)生在細(xì)胞內(nèi)，并由宿主細(xì)胞酶進(jìn)行。Adefovir 的二磷酸化衍生物以病毒 DNA 聚合酶為靶點(diǎn)，還充當(dāng) DNA 鏈終止劑。腺苷酸激酶被證明負(fù)責(zé)第一次磷酸化，隨后是 ADP 激酶和肌酸激酶，形成 Adefovir 二磷酸^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

不受食物影響，Adefovir 口服生物利用度達(dá)到 60%。其半衰期為 12-30 小時(shí)，Adefovir 經(jīng)腎臟排泄，無(wú)明顯代謝產(chǎn)物。Adefovir 基本上不影響細(xì)胞色素 P450^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

273.19

Formula

C₈H₁₂N₅O₄P

CAS 號(hào)

106941-25-7

性狀

固體

顏色

White to off-white

中文名稱(chēng)

阿德福韋

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲(chǔ)存方式

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性數(shù)據(jù)

細(xì)胞實(shí)驗(yàn)：

0.1 M NaOH 中的溶解度 : 10 mg/mL (36.60 mM; ultrasonic and adjust pH to 10 with NaOH)

H₂O 中的溶解度 : < 0.1 mg/mL (insoluble)

DMSO 中的溶解度 : < 1 mg/mL (insoluble or slightly soluble)

配制儲(chǔ)備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	3.6605 mL	18.3023 mL	36.6046 mL
5 mM	0.7321 mL	3.6605 mL	7.3209 mL
10 mM	0.3660 mL	1.8302 mL	3.6605 mL

查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

摩爾計(jì)算器
稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

掃碼獲得
動(dòng)物溶解方案

動(dòng)物溶解方案計(jì)算器

請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只

由于實(shí)驗(yàn)過(guò)程有損耗，建議您多配一只動(dòng)物的量

純度 & 產(chǎn)品資料

純度: 99.74%

選擇批次：

Data Sheet (616 KB) SDS (479 KB)

COA (284 KB) HNMR (117 KB) RP-HPLC (191 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻(xiàn)

[1]. X.-X.Zhou, et al. 7.11 - Deoxyribonucleic Acid Viruses: Antivirals for Herpesviruses and Hepatitis B Virus. Comprehensive Medicinal Chemistry II. Volume 7, 2007, Pages 295-327.

[2]. Marcellin P, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003 Feb 27;348(9):808-16. [Content Brief]

[3]. Leah A.Burke, et al. 155 - Drugs to Treat Viral Hepatitis. Infectious Diseases. Volume 2, 2017, Pages 1327-1332.

Adefovir 相關(guān)分類(lèi)

Infection

完整儲(chǔ)備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

0.1 M NaOH	1 mM	3.6605 mL	18.3023 mL	36.6046 mL	91.5114 mL
	5 mM	0.7321 mL	3.6605 mL	7.3209 mL	18.3023 mL
	10 mM	0.3660 mL	1.8302 mL	3.6605 mL	9.1511 mL
	15 mM	0.2440 mL	1.2202 mL	2.4403 mL	6.1008 mL
	20 mM	0.1830 mL	0.9151 mL	1.8302 mL	4.5756 mL
	25 mM	0.1464 mL	0.7321 mL	1.4642 mL	3.6605 mL
	30 mM	0.1220 mL	0.6101 mL	1.2202 mL	3.0504 mL

產(chǎn)品名稱(chēng)：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機(jī)構(gòu)名稱(chēng)：
留言給我們：

產(chǎn)品名稱(chēng)：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門(mén)：
* 公司或機(jī)構(gòu)名稱(chēng)：
留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報(bào)的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個(gè)人或者非科研性質(zhì)的、非用于藥證申報(bào)使用等其他用途提供服務(wù)。	站點(diǎn)地圖隱私聲明
滬ICP備15051369號(hào)-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營(yíng)業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Adefovir (Synonyms: 阿德福韋; GS-0393; PMEA)

Customer Review

Other Forms of Adefovir:

MCE 顧客使用本產(chǎn)品發(fā)表的 1 篇科研文獻(xiàn)

Adefovir 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

生物活性

純度 & 產(chǎn)品資料

參考文獻(xiàn)

摩爾計(jì)算器

稀釋計(jì)算器

Adefovir 相關(guān)分類(lèi)

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

熱門(mén)區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Adefovir (Synonyms: 阿德福韋; GS-0393; PMEA)

Customer Review

Other Forms of Adefovir:

MCE 顧客使用本產(chǎn)品發(fā)表的 1 篇科研文獻(xiàn)

Adefovir 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

生物活性

純度 & 產(chǎn)品資料

參考文獻(xiàn)

摩爾計(jì)算器

稀釋計(jì)算器

Adefovir 相關(guān)分類(lèi)

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

Request for HNMR Report

Request for HNMR Report

熱門(mén)區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z